Fig. 2From: Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19Risk of adverse clinical outcomes associated with hypertension and the use of RAAS-blocking agents. RAAS, renin-angiotensin-aldosterone-system; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockersBack to article page